LLAI Lunglife Ai Inc

LungLife AI, Inc.
(the "Company" or "LungLife")

LungLife to present at US National Cancer Institute's Early Detection Research Network Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces it has been invited to present at the National Cancer Institute's ("NCI") Early Detection Research Network ("EDRN") meeting in Tempe, Arizona on 17 April 2024.

The EDRN is a division of the United States NCI, the federal government's principal agency for cancer research and training, which works collaboratively amongst its members to bring new diagnostic biomarkers to clinical use.

In October 2022, LungLife was selected to participate in the Lung Cancer Biomarker Development Laboratory of the EDRN, combining LungLB® with imaging to assist early detection research, as well as validate combined test performance in patients with indeterminate lung nodules.

In this meeting, LungLife will present the LungLB® test, including results from the validation study and information on the Early Access Program, and describe its role in the ongoing EDRN study for indeterminate lung nodules to a group of over 300 investigators from the NCI, academic institutions and industry focused on early cancer detection.

Paul Pagano, CEO of LungLife AI, said "We are excited that through our ongoing EDRN partnership we have the opportunity to present at this meeting to collaborators and potential end users of LungLB®.

"The work of the EDRN closely aligns with LungLife's mission to drive the early detection of lung cancer and will provide further clinical evidence for the LungLB® technology as well as widen awareness of our technology with leading US investigators and diagnostics industry partners."

For further information please contact:

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

About Lung Cancer

Lung cancer is the most fatal form of cancer worldwide and early detection is critical to achieve better outcomes. Early detection involves the evaluation of indeterminate lung nodules, of which there are over 1.5M identified by CT scan each year in the United States alone. Evaluation often involves significant unnecessary invasive procedures such as biopsy for patients with benign nodules and long delays in potentially curative treatment for patients with cancerous nodules that are selected for monitoring via non-invasive imaging. LungLB® is intended to help with earlier diagnosis in the evaluation process.